Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.68 |
| ▸ | LPL | P06858 | 11/20 | 0.68 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478527 | 1.00 | LIPG (0.68) | LIPGLPLF11CYP4F2CYP4A11 | |
| SCHEMBL16936864 | 0.91 | LIPG (0.74) | LIPGLPLF11CYP4F2CYP4A11 | |
| SCHEMBL1284463 | 0.87 | LIPG (0.63) | LIPGLPLF11ROCK1ESR2 | |
| SCHEMBL23071684 | 0.85 | LIPG (0.70) | LIPGLPLF11DGAT1 | |
| SCHEMBL30477495 | 0.85 | LIPG (0.80) | LIPGLPLF11ESR2DGAT1 | |
| SCHEMBL12215735 | 0.85 | LIPG (0.80) | LIPGLPLF11ESR2DGAT1 | |
| SCHEMBL4751545 | 0.84 | LIPG (0.68) | LIPGLPLF11 | |
| SCHEMBL25813029 | 0.84 | LIPG (0.68) | LIPGLPLF11ESR2DGAT1 | |
| SCHEMBL24837499 | 0.83 | LIPG (0.67) | LIPGLPLF11ROCK1ESR2 | |
| SCHEMBL14750160 | 0.83 | LIPG (0.91) | LIPGLPLF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235840-A1 | ECHINOCANDIN-LIKE AND BORON-CONTAINING ECHINOCANDIN COMPOUNDS AND THEIR USE AS AGROCHEMICAL FUNGICIDES | 5METIS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4146658-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2023-03-15 | — | — | EP | disclosed |
| CN-107805311-B | Dynamic polymer with hybrid cross-linked network and application thereof | 翁秋梅 | 2022-04-01 | — | — | CN | disclosed |
| CN-107074801-B | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclenones as antioxidant inflammatory modulators | 里亚塔医药公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3097089-B1 | ARYL AND ARYLALKYL SUBSTITUTED PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS INC (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-111378168-A | Combined energy absorption method and application thereof | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111040203-A | Energy absorption method based on hybrid cross-linked dynamic polymer | 翁秋梅 | 2020-04-21 | — | — | CN | disclosed |
| US-10064861-B2 | Macrocyclic pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2018-09-04 | — | — | US | disclosed |
| EP-2864318-B1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| EP-2864318-B1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-7605266-B2 | Azaindole inhibitors of Aurora kinases | SMITHKLINE BEECHAM (US) | 2009-10-20 | — | — | US | disclosed |
| US-7495102-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
| US-7425563-B2 | Excellent poly (ADP-ribose) synthetase inhibitors; various ischemic diseases, inflammatory diseases, neurodegenerative diseases, diabetes, septic shock, cephalic injury; 1,2-Dihydro-4-[4-(dimethylaminomethyl)phenyl]-5-hydroxy-1-oxoisoquinoline | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425563-B2 | Excellent poly (ADP-ribose) synthetase inhibitors; various ischemic diseases, inflammatory diseases, neurodegenerative diseases, diabetes, septic shock, cephalic injury; 1,2-Dihydro-4-[4-(dimethylaminomethyl)phenyl]-5-hydroxy-1-oxoisoquinoline | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7419988-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORP (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064861-B2 | Macrocyclic pyridazinone derivatives | C5, PDXK, CYP1A2 | LIPG 3202/4885LPL 1097/4885F11 1100/4885 |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | LIPG 4630/4885LPL 4835/4885F11 3791/4885 |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | LIPG 4630/4885LPL 4835/4885F11 3791/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | LIPG 4630/4885LPL 4835/4885F11 3791/4885 |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | AURKA, AURKC, AURKB | LIPG 4809/4885LPL 4883/4885F11 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.